Welcome To The Quigley Corporation

The information presented provides an introduction to the Company and its subsidiaries. This site has been designed to provide a resource for news and financial data as well as information on the Company.

Mission
Our mission is to develop and market natural health care pharmaceuticals and nutriceuticals that offer pioneering new options to improve patient treatment results. Our core objective is to address the root cause of illness with the goal of exceeding the efficacy and safety of current treatment options. This approach includes the development of natural compounds and unique methods to deliver those compounds in an effort to innovate medical science and improve patient outcomes.

Consumer Health
Our consumer health products, marketed through The Quigley Corporation and certain subsidiaries, include the original COLD-EEZE®. COLD-EEZE® contains the only safe and effective natural formula that has been shown to significantly reduce the duration of the common cold in repeated clinical trials. It offers a significant advancement over the majority of cough/cold products available over-the-counter, which do not reduce the duration of the common cold. A recent retrospective analysis also suggests that COLD-EEZE® is an effective means of prevention. The study indicated that when taken daily, COLD-EEZE® statistically lessens the number of colds an individual suffers per year, reducing the median from 1.5 to zero. The scientific results of clinical testing have propelled COLD-EEZE® to a top selling Cough Cold brand in record time.

Ethical Pharmaceuticals
The mission and philosophy of The Quigley Corporation extends to Quigley Pharma Inc., a wholly owned ethical pharmaceutical subsidiary. Quigley Pharma combines the rigor of traditional pharmaceutical research with an eye toward revolutionary technologies and treatment approaches to effectively improve the health and wellness of society.

The research pipeline for Quigley Pharma includes several natural compounds currently undergoing rigorous analysis for their application with difficult-to-treat disease states. The goal is to confirm the efficacy of these compounds according to the requirements set forth by the U.S. Food & Drug Administration in order to market them as ethical pharmaceuticals.